Elevated levels of serum fatty acid synthase in patients with gastric carcinoma

Ito,Tomoaki; Sato,Koichi; Maekawa,Hiroshi; Sakurada,Mutsumi; Orita,Hajime; Shimada,Kazunori; Daida,Hiroyuki; Wada,Ryo; Abe,Masaaki; Hino,Okio; Kajiyama,Yoshiaki

doi:10.3892/ol.2014.1793

Elevated levels of serum fatty acid synthase in patients with gastric carcinoma

Authors:
- Tomoaki Ito
- Koichi Sato
- Hiroshi Maekawa
- Mutsumi Sakurada
- Hajime Orita
- Kazunori Shimada
- Hiroyuki Daida
- Ryo Wada
- Masaaki Abe
- Okio Hino
- Yoshiaki Kajiyama
View Affiliations

Affiliations: Department of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Shizuoka, Japan, Department of Cardiovascular Medicine, Juntendo University School of Medicine, Tokyo, Japan, Department of Pathology, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Shizuoka, Japan, Department of Pathology and Oncology, Juntendo University School of Medicine, Tokyo, Japan, Department of Esophageal and Gastroenterological Surgery, Juntendo University School of Medicine, Tokyo, Japan
Published online on: January 14, 2014 https://doi.org/10.3892/ol.2014.1793
Pages: 616-620

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is the second leading cause of cancer mortality in the world. It is important to develop biomarkers for detecting new cancers at an early stage and for treating them early during recurrence in order to guide optimal treatment. Fatty acid synthase (FAS) is highly expressed in numerous human cancers and thus could potentially serve as such a biomarker, but the potential utility of measuring FAS for detecting gastric cancer has not been previously investigated. The aim of the present study was to provide a preliminary assessment of serum FAS as a marker of gastric carcinoma. The study included 47 patients with gastric cancer and 150 healthy subjects. Blood samples were collected from each cancer patient prior to treatment. Serum FAS levels were measured by ELISA and compared across the two groups of patients. Significantly higher levels of serum FAS were found in the gastric cancer patients [95% confidence interval (CI), 30.37‑52.46] compared with the healthy controls (95% CI, 1.331‑2.131), with elevated levels even in patients with early‑stage tumors. These results indicate that measuring serum FAS levels has strong potential to provide a biomarker for the detection of gastric cancer, with high sensitivity and specificity.

View Figures

View References

1	Kelley JR and Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003. View Article : Google Scholar : PubMed/NCBI
2	Jian P, Yanfang T, Zhuan Z, Jian W, Xueming Z and Jian N: MMP28 (epilysin) as a novel promoter of invasion and metastasis in gastric cancer. BMC Cancer. 11:2002011. View Article : Google Scholar : PubMed/NCBI
3	Gao C, Xie R, Ren C and Yang X: Dickkopf-1 expression is a novel prognostic marker for gastric cancer. J Biomed Biotechnol. 2012:8045922012.PubMed/NCBI
4	Kuhajda FP: Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66:5977–5980. 2006. View Article : Google Scholar : PubMed/NCBI
5	Kuhajda FP, Jenner K, Wood FD, et al: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 91:6379–6383. 1994. View Article : Google Scholar : PubMed/NCBI
6	Alo’ PL, Visca P, Marci A, Mangoni A, Botti C and Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 77:474–482. 1996.PubMed/NCBI
7	Milgraum LZ, Witters LA, Pasternack GR and Kuhajda FP: Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res. 3:2115–2120. 1997.PubMed/NCBI
8	Swinnen JV, Roskams T, Joniau S, et al: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 98:19–22. 2002. View Article : Google Scholar : PubMed/NCBI
9	Ogino S, Nosho K, Meyerhardt JA, et al: Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 26:5713–5720. 2008. View Article : Google Scholar : PubMed/NCBI
10	Orita H, Coulter J, Tully E, Kuhajda FP and Gabrielson E: Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res. 14:2458–2464. 2008. View Article : Google Scholar : PubMed/NCBI
11	Sugino T, Baba K, Hoshi N, Aikawa K, Yamaguchi O and Suzuki T: Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. Med Mol Morphol. 44:146–150. 2011. View Article : Google Scholar : PubMed/NCBI
12	Gansler TS, Hardman W III, Hunt DA, Schaffel S and Hennigar RA: Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 28:686–692. 1997. View Article : Google Scholar
13	Kusakabe T, Nashimoto A, Honma K and Suzuki T: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology. 40:71–79. 2002. View Article : Google Scholar
14	Orita H, Coulter J, Tully E, et al: High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy. Cancer Biol Ther. 10:549–554. 2010. View Article : Google Scholar
15	Pizer ES, Lax SF, Kuhajda FP, Pasternack GR and Kurman RJ: Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer. 83:528–537. 1998. View Article : Google Scholar
16	Sebastiani V, Visca P, Botti C, et al: Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol. 92:101–105. 2004. View Article : Google Scholar : PubMed/NCBI
17	Alo PL, Amini M, Piro F, et al: Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res. 27:2523–2527. 2007.PubMed/NCBI
18	Walter K, Hong SM, Nyhan S, et al: Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 18:2380–2385. 2009. View Article : Google Scholar : PubMed/NCBI
19	Horiguchi A, Asano T, Ito K, Sumitomo M and Hayakawa M: Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 180:1137–1140. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mashima T, Seimiya H and Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 100:1369–1372. 2009. View Article : Google Scholar : PubMed/NCBI
21	Rashid A, Pizer ES, Moga M, et al: Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol. 150:201–208. 1997.PubMed/NCBI
22	Piyathilake CJ, Frost AR, Manne U, et al: The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol. 31:1068–1073. 2000. View Article : Google Scholar : PubMed/NCBI
23	Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS and Nelson JB: Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 47:102–110. 2001. View Article : Google Scholar : PubMed/NCBI
24	Gabrielson EW, Pinn ML, Testa JR and Kuhajda FP: Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 7:153–157. 2001.PubMed/NCBI
25	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Kuhajda FP, Li JN, et al: Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 167:99–104. 2001. View Article : Google Scholar : PubMed/NCBI
27	Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, et al: Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncol. 35:1369–1376. 2009.
28	Wang Y, Kuhajda FP, Sokoll LJ and Chan DW: Two-site ELISA for the quantitative determination of fatty acid synthase. Clin Chim Acta. 304:107–115. 2001. View Article : Google Scholar : PubMed/NCBI
29	Notarnicola M, Tutino V, Calvani M, Lorusso D, Guerra V and Caruso MG: Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage. J Gastrointest Cancer. 43:508–511. 2012. View Article : Google Scholar : PubMed/NCBI
30	Lukaszewicz-Zając M, Mroczko B, Gryko M, Kędra B and Szmitkowski M: Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med. 11:89–96. 2011.
31	Schneider J and Schulze G: Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res. 23:5089–5093. 2003.